Volume : 08, Issue : 02, February – 2021

46.SHIGELLOSIS (BACILLARY DYSENTERY): A REVIEW

Savitha Mol. G. M*, Silvia Navis A, Prasobh G R

Abstract :

Shigellosis is an acute infection of the intestine caused by bacteria in the genus Shigella. There are 4 species of Shigella: S. dysenteriae, S. flexneri, S. boydii, and S. sonnei (also referred to as group A, B, C, and D, respectively). Several distinct serotypes are recognized within the first 3 species. The accurate estimate of morbidity and mortality is lacking in case of shigellosis. This review is focused upon the epidemiology, disease burden and therapeutic approaches and developments of shigellosis.
Key Words: Shigella, diarrhea, Enterobacteriaceae, shigellosis

Cite This Article:

Please cite this article in press Savitha Mol. G. M et al, Shigellosis (Bacillary Dysentery): A Review., Indo Am. J. P. Sci, 2021; 08(02).

Number of Downloads : 10

References :

References :

1. DuPont HL. Shigella species (bacillary dysentery). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone Elsevier; 2010. p. 2905-10.
2. Kotloff K, Ivanoff B, Clemens J, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Heal Organ. 1999;77(8):651- 66.
3. Kotloff K, Blackwelder W, Nataro J. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2013;382 (209-222).
4. Lanata CF, Fischer-Walker CL, Olascoaga AC, et al. Global Causes of Diarrheal Disease Mortality in Children <5 Years of Age: A Systematic Review. Sestak K, ed. PLoS One. 2013;8(9):e72788.
5. Zhang, Q. Wang, J. Chu, X. Li-Meng, S. Yuan, Y. Liu C. Epidemic and virulence characteristic of Shigella spp. with extended-spectrum cephalosporin resistance in Xiaoshan District, Hangzhou, China. BMC Infect Dis. 2014;14 (260.).
6. Manning P, Lon C, Spring M, et al. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Ch. 2014;58 (10):6056-7.
7. Sykes I, Mtove G, Mandea V, Mrema H, Hendriksen A. Azithromycin plus Artesunate versus Artemether-Lumefantrine for Treatment of Uncomplicated Malaria in Tanzanian Children: A Randomized, Controlled Trial. Clin Infect Dis. 2009;49 (8):1195-1201.
8. Torres AG. Current aspects of Shigella pathogenesis. Rev Latinoam Microbiol 2004;46: 89-97.
9. Niyogi SK. Shigellosis. J Microbiol 2005; 43 : 133-43.Sharma A, Singh SK, Bajpai D. Phenotypic and genotypic characterization of Shigella spp. with reference to its virulence genes and antibiogram analysis from river Narmada. Indian J Microbiol 2009; 49 : 259-65.
10. Dorman CJ, Porter ME. The Shigella virulence gene regulatory cascade: a paradigm of bacterial gene control mechanisms. Mol Microbiol 1998; 29 : 677-84.
11. Marcus U, Zucs P, Braemer V et al. Cluster of shigellosis in men in Berlin in 2001. Eurosurveillance 2002; 6: Issue 33.
12. Notifiable Disease Surveillance System, Surveillance and Epidemiology Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada (2005-2008).
13. Ravel A, Nesbitt A, Marshall B et al. Description and Burden of Travel-Related Cases Caused by Enteropathogens Reported in a Canadian Community. Journal of Travel Medicine 2011; 18(1): 8-19.
14. Aragon TJ, Vugia DJ, Shallow S et al. Case Control Study of Shigellosis in San Francisco: The Role of Sexual Transmission and HIV Infection; oral-anal sex, MSM. Clinical Infectious Diseases 2007; 44: 327-334.
15. Weir E. Shigella: Wash your hands of the whole dirty business. CMAJ 2002; 167 (3): 281.
16. Bowen A, Hurd J, Hoover C, Khachadourian Y, Traphagen E, Harvey E, Libby T, Ehlers S, Ongpin M, Norton JC, et al. Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin-United States, May 2014–February 2015. MMWR Morb Mortal Wkly Rep. 2015;64:318–20.
17. Pourakbari B, Mamishi S, Mashoori N, Mahboobi N, Ashtiani MH, Afsharpaiman S, Abedini M. Frequency and antimicrobial susceptibility of Shigella species isolated in Children Medical Center Hospital, Tehran, Iran, 2001–2006. Braz J Infect Dis. 2010;14: 153–7.
18. Mandell W, Neu H Shigella bacterimia in adults, JAMA 1986; 255: 3116-7.
19. Freeman, Newman H, Abrahamas R, Shigella keratitis is an HIV- exposed infact, Pediatr Infect Dis J 2013: 32 436-7
20. Torres AG, Current aspects of shigella pathogenesis Rev Latinoam Micobiol 2004; 46: 89-97
21. Panigrahi D et al. Incidence of shigellosis and multi-drug resistant Shigellae: a 10-year study. Journal of tropical medicine and hygiene, 1987, 90: 25±29
22. Ashkenazi S et al. Recent trends in the epidemiology of Shigella species in Israel. Clinical infectious diseases, 1993, 17: 897±899.
23. Van de Verg LL et al. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection. Vaccine, 1996, 14: 1062±1068.
24. Akman M. Shigella types found in Ankara: an analysis of 332 isolated strains. Turkish journal of pediatrics, 1965, 7: 154±160.